<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717234</url>
  </required_header>
  <id_info>
    <org_study_id>14.31.US.CLI</org_study_id>
    <nct_id>NCT02717234</nct_id>
  </id_info>
  <brief_title>Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement</brief_title>
  <official_title>Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of consumption of an oral nutrition supplement on Arginine, a blood
      marker of nutritional intake
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma arginine levels in µmol/L</measure>
    <time_frame>Pre-consumption, 30, 60, 120, 180, 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma-free phospholipid Eicosapentaenoic acid (EPA) in µg/ml</measure>
    <time_frame>Pre-consumption, 30, 60, 120, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma phospholipid Eicosapentaenoic acid (EPA) in µg/ml</measure>
    <time_frame>Pre-consumption, 30, 60, 120, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma-free phospholipid Docosahexaenoic acid (DHA) in µg/ml</measure>
    <time_frame>Pre-consumption, 30, 60, 120, 180, 240 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in plasma phospholipid Docosahexaenoic acid (DHA) in µg/ml</measure>
    <time_frame>Pre-consumption, 30, 60, 120, 180, 240 minutes</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Impact Advanced Recovery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral nutrition supplement intended for consumption at 3 servings per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Impact Advanced Recovery-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral nutrition supplement intended for consumption at 3 servings per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Nutrition Supplement</intervention_name>
    <description>Oral nutrition supplement intended for consumption at 3 servings per day</description>
    <arm_group_label>Impact Advanced Recovery</arm_group_label>
    <arm_group_label>Impact Advanced Recovery-R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject (absence of metabolic disorder, heart disease, endocrine disease,
             cancer)

          -  Discontinued use of omega 3 fatty acid supplements - 10 days prior to testing

          -  Willing to provide signed informed consent

        Exclusion Criteria:

          -  Smoker

          -  Patients with potential for non-compliance

          -  Patients with allergy to ingredients in test products (i.e. milk protein, fish oil)

          -  Subject who in the Investigator's assessment cannot be expected to comply with study
             protocol

          -  Currently participating in another conflicting clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherwyn Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes &amp; Glandular Disease Clinic, PA</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

